Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib.
Aglietta M, Chiarion-Sileni V, Fava P, Guidoboni M, Depenni R, Minisini A, Consoli F, Ascierto PA, Rinaldi G, Banzi M, Marconcini R, Gueli R, Ferraresi V, Tucci M, Tonini G, Lo Re G, Guida M, Del Vecchio M, Marcon IG, Queirolo P. Aglietta M, et al. Among authors: rinaldi g. Tumori. 2023 Dec;109(6):537-545. doi: 10.1177/03008916231179251. Epub 2023 Jul 7. Tumori. 2023. PMID: 37417313 Free PMC article.
The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study.
Del Vecchio M, Chiarion Sileni V, Quaglino P, Rinaldi G, Minisini A, Troiani T, Consoli F, Sponghini A, Banzi M, Morelli MF, Palleschi D, Rossi E, Marconcini R, Depenni R, Carnevale-Schianca F, Marcon I, Queirolo P. Del Vecchio M, et al. Among authors: rinaldi g. Cancers (Basel). 2023 Mar 26;15(7):1980. doi: 10.3390/cancers15071980. Cancers (Basel). 2023. PMID: 37046641 Free PMC article.
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA, Di Giacomo AM, Chiarion Sileni V, Queirolo P, Spagnolo F, De Galitiis F, Cognetti F, Mandalà M, Guidoboni M, Rinaldi G, Depenni R, Consoli F, Troiani T, Guida M, Marconcini R, Ferrucci PF, Strippoli S, Fava P, Merelli B, Simeone E, Di Guardo L, Giannarelli D, Maio M, Quaglino P, Del Vecchio M. Ascierto PA, et al. Among authors: rinaldi g. Eur J Cancer. 2023 Sep;191:113246. doi: 10.1016/j.ejca.2023.113246. Epub 2023 Jul 19. Eur J Cancer. 2023. PMID: 37549531
Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program.
Quaglino P, Ascierto PA, Consoli F, Queirolo P, Spagnolo F, Morelli MF, Berardi R, Chiarion-Sileni V, Tucci M, Troiani T, Melotti B, Rossi E, Mandala M, Rinaldi G, Marcon IG, Pizzuti M, Del Vecchio M. Quaglino P, et al. Among authors: rinaldi g. Cancer Manag Res. 2023 Nov 11;15:1271-1281. doi: 10.2147/CMAR.S423970. eCollection 2023. Cancer Manag Res. 2023. PMID: 38027240 Free PMC article.
Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective Analysis.
Hench J, Mihic-Probst D, Agaimy A, Frank S, Meyer P, Hultschig C, Simi S, Alos L, Balamurugan T, Blokx W, Bosisio F, Cappellesso R, Griewank K, Hadaschik E, van Kempen LC, Kempf W, Lentini M, Mazzucchelli L, Rinaldi G, Rutkowski P, Schadendorf D, Schilling B, Szumera-Cieckiewicz A, van den Oord J, Mandalà M, Massi D; EORTC Melanoma Group. Hench J, et al. Among authors: rinaldi g. Eur J Cancer. 2023 Jul;187:7-14. doi: 10.1016/j.ejca.2023.03.032. Epub 2023 Apr 2. Eur J Cancer. 2023. PMID: 37098294 Free article.
BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants?
Fanale D, Corsini LR, Brando C, Randazzo U, Bono M, Pedone E, Perez A, Sciacchitano R, Cancelliere D, Piraino P, Giurintano A, Bazan Russo TD, Ferraro P, Rinaldi G, Spinnato V, Gennusa V, Pernice G, Vieni S, Pantuso G, Russo A, Bazan V. Fanale D, et al. Among authors: rinaldi g. Front Oncol. 2024 Jun 21;14:1414343. doi: 10.3389/fonc.2024.1414343. eCollection 2024. Front Oncol. 2024. PMID: 38974244 Free PMC article.
miR-449a/miR-340 reprogram cell identity and metabolism in fusion-negative rhabdomyosarcoma.
Pozzo E, Yedigaryan L, Giarratana N, Wang CC, Garrido GM, Degreef E, Marini V, Rinaldi G, van der Veer BK, Sassi G, Eelen G, Planque M, Fanzani A, Koh KP, Carmeliet P, Yustein JT, Fendt SM, Uyttebroeck A, Sampaolesi M. Pozzo E, et al. Among authors: rinaldi g. Cell Rep. 2025 Jan 11;44(1):115171. doi: 10.1016/j.celrep.2024.115171. Online ahead of print. Cell Rep. 2025. PMID: 39799567 Free article.
Neuropsychological tests at the Italian Centers for Cognitive Disorders and Dementias: results from a survey on 450 specialized services.
Vaccaro R, Lorenzini P, Giaquinto F, Matascioli F, Carnevale G, Sciancalepore F, Gasparini M, Salvi E, Corbo M, Locuratolo N, Vanacore N, Bacigalupo I; Permanent Table of the National Dementia Plan Study Group; CCDDs Study Group. Vaccaro R, et al. Aging Clin Exp Res. 2024 Dec 20;37(1):1. doi: 10.1007/s40520-024-02869-6. Aging Clin Exp Res. 2024. PMID: 39704981 Free PMC article.
471 results